Healthby Marina Temkin
Efferon Battles Pediatric Sepsis with Blood-Purification Tech
Key Takeaways
- Efferon developed a blood-purification device specifically for pediatric sepsis.
- The Efferon NEO device simultaneously absorbs both endotoxins and cytokines.
- The startup secured a CE mark in Europe and plans to seek FDA approval.
- The technology is currently used in intensive care units across 30 countries.
Efferon has introduced a specialized medical device designed to tackle pediatric sepsis, a leading cause of childhood mortality globally. The device filters the blood to remove both endotoxins and dangerous cytokines simultaneously, setting it apart from standard adult treatments. Having received a CE mark in Europe, Efferon NEO is already deployed in intensive care units across 30 countries while the company eyes US expansion.
Recommended for you
Tools and services we trust to boost productivity and content workflows.
Browse picks